Company Overview

BillionToOne, Inc. is a privately held molecular diagnostics company operating in the biotechnology and clinical diagnostics industries. The company develops and commercializes advanced DNA-based diagnostic tests that leverage its proprietary quantitative molecular counting technology to improve accuracy in detecting genetic variations. Its core focus areas include reproductive health, oncology, and genetic disease screening, serving clinicians, laboratories, and healthcare systems.

The company’s primary revenue drivers are its commercially available diagnostic tests, particularly non-invasive prenatal screening (NIPS) products and oncology liquid biopsy assays. BillionToOne, Inc. positions itself through a technology platform designed to overcome limitations of traditional next-generation sequencing by accurately counting individual DNA molecules, which it markets as a key differentiator in sensitivity and specificity. Founded in 2016, the company evolved from a technology-focused startup into a commercial-stage diagnostics provider, expanding its test menu and clinical adoption through regulatory progress and peer-reviewed validation.

Business Operations

BillionToOne, Inc. operates through integrated research, development, laboratory, and commercial functions. Its business is organized around two primary product lines: UNITY™, a carrier screening and non-invasive prenatal test portfolio for reproductive health, and Northstar™, an oncology-focused liquid biopsy platform used for therapy selection and disease monitoring. Revenue is generated through test reimbursement, institutional contracts, and clinical testing services performed in its certified laboratories.

Operations are primarily based in the United States, with laboratory services conducted in CLIA-certified and CAP-accredited facilities. The company controls proprietary molecular counting technology, bioinformatics pipelines, and assay designs. Public disclosures confirm no large-scale joint ventures; however, BillionToOne, Inc. collaborates with healthcare providers, academic institutions, and pharmaceutical partners to support clinical validation and oncology applications. Data on smaller partnerships is limited in public sources.

Strategic Position & Investments

The company’s strategic direction emphasizes expanding adoption of precision diagnostics in reproductive genetics and precision oncology. Growth initiatives include broadening clinical indications for its existing tests, increasing payer coverage, and integrating its assays into standard-of-care workflows. BillionToOne, Inc. has raised multiple rounds of venture financing to support commercialization, R&D, and laboratory expansion, with funding participation from established life sciences investors.

Investment activity has focused on internal technology development rather than large acquisitions. Publicly available information does not confirm material acquisitions of other companies as of the most recent reporting period; therefore, data on significant acquired entities is inconclusive based on available public sources. The company is actively involved in emerging applications of liquid biopsy, minimal residual disease detection, and highly multiplexed genetic analysis.

Geographic Footprint

BillionToOne, Inc. is headquartered in California, United States, and its primary operations, laboratories, and commercial activities are concentrated in the United States. The company serves clinicians and patients nationwide through centralized laboratory testing and logistics networks.

While its products may be used for patients with international backgrounds or global pharmaceutical research collaborations, there is no verified evidence of owned laboratories or material operational infrastructure outside North America. International expansion has been discussed in general terms in investor communications, but confirmed operational presence beyond the U.S. remains limited based on public disclosures.

Leadership & Governance

The company was founded by Oguzhan Atay, who established the organization around a technology-driven approach to molecular counting and precision diagnostics. Leadership emphasizes scientific rigor, clinical validation, and scalable healthcare impact, with governance aligned to venture-backed private company standards.

Key executives include:

• Oguzhan Atay – Chief Executive Officer and Founder
• Gary Palmer – Chief Medical Officer
• Jamie Platt – Chief Commercial Officer
• Thomas Lee – Chief Financial Officer
• Yvonne Chien – Chief Technology Officer

Leadership information is based on company disclosures and external business profiles; minor discrepancies in executive titles or tenure exist across sources, but roles listed above are consistently reported in multiple reputable public records.